Nociceptin attenuates methamphetamine abstinence-induced withdrawal-like behavior in planarians

Neuropeptides

Volumn 42, Issue 3, 2008, Pages 229-237

  Rawls, Scott M ^a   Baron, Steven ^a   Ding, Zhe ^a   Roth, Christopher ^a   Zaveri, Nurulain ^b   Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

JTC 801; Methamphetamine; Nociceptin; Nociceptin orphanin FQ; Planaria; Withdrawal

Indexed keywords

METHAMPHETAMINE; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; NOCICEPTIN; WATER;

ARTICLE; ATTENUATION; BEHAVIOR; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; HYPOTHESIS; LOCOMOTION; MAMMAL; MODULATION; NONHUMAN; PRIORITY JOURNAL; TURBELLARIA;

AMINOQUINOLINES; ANIMALS; BENZAMIDES; CENTRAL NERVOUS SYSTEM STIMULANTS; METHAMPHETAMINE; MOTOR ACTIVITY; OPIOID PEPTIDES; PLANARIANS; RECEPTORS, OPIOID; SUBSTANCE WITHDRAWAL SYNDROME;

MAMMALIA; PLANARIA; TURBELLARIA;

EID: 44649092656     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2008.03.005     Document Type: Article

References (57)

1. Algeri S., Carolei A., Ferretti P., Gallone C., Palladini G., and Venturini G. Effects of dopaminergic agents on monoamine levels and motor behaviour in planaria. Comp. Biochem. Physiol. C 74 (1983) 27-29
2. Bertorelli R., Calò G., Ongini E., and Regoli D. Nociceptin/orpanin FQ and its receptor: a potential target for drug discovery. Trends Pharmacol. Sci. 21 (2000) 233-234
3. Brown J.M., Gouty S., Iyer V., Rosenberger J., and Cox B.M. Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. J. Neurochem. 98 (2006) 495-505
4. Calo G., Rizzi A., Bigoni R., Guerrini R., Salvadori S., and Regoli D. Pharmacological profile of nociceptin/orphanin FQ receptors. Clin. Exp. Pharmacol. Physiol. 29 (2002) 223-228
5. Cebria F., Kudome T., Nakazawa M., Mineta K., Ikeo K., Gojobori T., and Agata K. The expression of neural-specific genes reveals the structural and molecular complexity of the planarian central nervous system. Mech. Dev. 116 (2002) 199-204
6. Chen X., McClatchy D.B., Geller E.B., Liu-Chen L., Tallarida R.J., and Adler M.W. Possible mechanism of hypothermia-induced by intracerebroventricular injection of orphanin FQ/nociceptin. Brain Res. 904 (2001) 252-258
7. Ciccocioppo R., Economidou D., Fedeli A., and Massi M. The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol Behav. 79 (2000) 121-128
8. Ciccocioppo R., Angeletti S., Sanna P.P., Weiss F., and Massi M. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur. J. Pharmacol. 404 (2000) 153-159
9. Cox D., Bowers R., and McBride A. Reboxetine may be helpful in the treatment of amphetamine withdrawal. Brit. J. Clin. Pharmacol. 58 (2004) 100-101
10. Eriksson K.S., and Panula P. γ-Aminobutyric acid in the nervous system of a planarian. J. Comp. Neurol. 345 (1994) 528-536
11. Florin S., Suaudeau C., Meunier J.C., and Costentin J. Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur. J. Pharmacol. 317 (1996) 9-13
12. Kavaliers M., and Perrot-Sinal T.S. Pronociceptive effects of the neuropeptide, nociceptin, in the land snail, Cepaea nemoralis. Peptides 17 (1996) 763-768
13. Kavaliers M., Choleris E., and Saucier D.M. The NMDA receptor antagonist, NPC 12626, reduces the pronociceptive effects of orphanin FQ and kappa opiate antinociception in the land snail, Cepaea nemoralis. Peptides 18 (1997) 943-947
14. Kimmel H.D., and Garrigan H.A. Resistance to extinction in planaria. J. Exp. Psychol. 101 (1973) 343-347
15. Kitanaka J., Kitanaka N., and Takemura M. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: a review. Neurochem. Res. 33 (2008) 204-219
16. Kotlinska J., Rafalski P., Biala G., Dylag T., Rolka K., and Silberring J. Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats. Eur. J. Pharmacol. 474 (2003) 233-239
17. Kusayama T., and Watanabe S. Reinforcing effects of methamphetamine in planarians. Neuroreport 11 (2000) 2511-2513
18. Kuzmin A., Sandin J., Terenius L., and Ogren S.O. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J. Pharmacol. Exp. Ther. 304 (2003) 310-318
19. León-Olea M., Miller-Pérez C., Cruz R., Antón B., Vega R., and Soto E. Immunohistochemical localization and electrophysiological action of nociceptin/orphanin-FQ in the snail (Helix aspersa) neurons. Neurosci. Lett. 316 (2001) 141-144
20. McGregor C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., and White J.M. The nature, time course and severity of methamphetamine withdrawal. Addiction 100 (2005) 1320-1329
21. Meunier J.C. Nociceptin/orphanin FQ and the opioid receptor-like (ORL1) receptor. Eur. J. Pharmacol. 340 (1997) 1-15
22. Mollereau C., and Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 21 (2000) 907-917
23. Murphy N.P., Lee Y., and Maidment N.T. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res. 832 (1999) 168-170
24. Murphy N.P., Tan A.M., Lam H.A., and Maidment N.T. Nociceptin/orphanin FQ modulation of rat midbrain dopamine neurons in primary culture. Neuroscience 127 (2004) 929-940
25. Needleman H.L. Tolerance and dependence in the planarian after continuous exposure to morphine. Nature 215 (1967) 784-785
26. Ness D.K., Foley G.L., Villar D., and Hansen L.G. Effects of 3-iodo-l-tyrosine, a tyrosine hydroxylase inhibitor, on eye pigmentation and biogenic amines in the planarian, Dugesia dorotocephala. Fundam. Appl. Toxicol. 30 (1996) 153-161
27. Newmark P.A., and Sanchez Alvarado A. Not your father's planarian: a classic model enters the era of functional genomics. Nat. Rev. Genet. 3 (2002) 210-219
28. Okabe C., and Murphy N.P. Short-term effects of the nociceptin receptor antagonist Compound B on the development of methamphetamine sensitization in mice: a behavioral and c-fos expression mapping study. Brain Res. 1017 (2004) 1-12
29. Okabe C., Takeshima H., and Murphy N.P. Methamphetamine sensitization in nociceptin receptor knockout mice: locomotor and c-fos expression. Eur. J. Pharmacol. 507 (2005) 57-67
30. Palladini G., Ruggeri S., Stocchi F., De Pandis M.F., Venturini G., and Margotta V. A pharmacological study of cocaine activity in planaria. Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 115 (1996) 41-45
31. Raffa R.B., Valdez J.M., Holland L.J., and Schulingkamp R.J. Energy-dependent UV light-induced disruption of (-)sulpiride antagonism of dopamine. Eur. J. Pharmacol. 406 (2000) R11-R12
32. Raffa R.B., and Valdez J.M. Cocaine withdrawal in planaria. Eur. J. Pharmacol. 430 (2001) 143-145
33. Raffa R.B., Holland L.J., and Schulingkamp R.J. Quantitative assessment of dopamine D2 antagonist activity using invertebrate (Planaria) locomotion as a functional endpoint. J. Pharmacol. Toxicol. Meth. 45 (2001) 223-226
34. Raffa R.B., Stagliano G.W., and Umeda S. κ-Opioid withdrawal in planaria. Neurosci. Lett. 349 (2003) 139-142
35. Raffa R.B., and Desai P. Description and quantification of cocaine withdrawal signs in Planaria. Brain Res. 1032 (2005) 200-202
36. Raffa R.B., and Martley A.F. Amphetamine-induced increase in planarian locomotor activity and block by UV light. Brain Res. 1031 (2005) 138-140
37. Raffa R.B., Stagliano G.W., and Tallarida R.J. Subadditive withdrawal from cocaine/κ-opioid agonist combinations in Planaria. Brain Res. 1114 (2006) 31-35
38. Raffa R.B., Cavallo F., and Capasso A. Flumazenil-sensitive dose-related physical dependence in planarians produced by two benzodiazepine and one non-benzodiazepine benzodiazepine-receptor agonists. Eur. J. Pharmacol. 564 (2007) 88-93
39. Rawls S.M., Gomez T., Stagliano G.W., and Raffa R.B. Measurement of glutamate and aspartate in planaria. J. Pharmacol. Toxicol. Meth. 53 (2006) 291-295
40. Rawls S.M., Rodriguez T., Baron D.A., and Raffa R.B. A nitric oxide synthase inhibitor (l-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in planaria. Brain Res. 1099 (2006) 82-87
41. Rawls S.M., Schroeder J.A., Ding Z., Rodriguez T., and Zaveri N. NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats. Neuropeptides 41 (2007) 239-247
42. Rawls S.M., Gomez T., and Raffa R.B. An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol. Biochem. Behav. 6 (2007) 499-504
43. Rawls S.M., Gomez T., and Raffa R.B. A TRPM8/TRPA1 channel agonist, icilin, a typically stimulates behavioral effects in planarians. Eur. J. Pharmacol. 575 (2007) 103-104
44. Rizzi A., Bigoni R., Marzola G., Guerrini R., Salvadori S., Regoli D., and Calo' G. Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn Schmiedebergs Arch. Pharmacol. 363 (2001) 161-165
45. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F.J., and Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
46. Rothman R.B., Partilla J.S., Baumann M.H., Dersch C.M., Carroll F.I., and Rice K.C. Neurochemical neutralization of methamphetamine with high-affinity non-selective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse 35 (2000) 222-227
47. Rothman R.B., and Baumann M.H. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann. NY Acad. Sci. 1074 (2006) 245-260
48. Sakoori K., and Murphy N.P. Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology (Berl) 172 (2004) 129-136
49. Sakoori K., and Murphy N.P. Endogenous nociceptin (Orphanin FQ) suppresses basal hedonic state and acute reward responses to methamphetamine and ethanol, but facilitates chronic responses. Neuropsychopharmacol. 33 (2008) 877-891
50. Saunders S.E., Burke J.F., and Benjamin P.R. Multimeric CREB-binding sites in the promoter regions of a family of G-protein-coupled receptors related to the vertebrate galanin and nociceptin/orphanin-FQ receptor families. Eur. J. Neurosci. 12 (2000) 2345-2353
51. Takamatsu Y., Yamamoto H., Ogai Y., Hagino Y., Markou A., and Ikeda K. Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. Ann. NY Acad. Sci. 1074 (2006) 295-302
52. Umeda S., Stagliano G.W., and Raffa R.B. Cocaine and κ-opioid withdrawal in Planaria blocked by d-, but not l-, glucose. Brain Res. 1018 (2004) 181-185
53. Varty G.B., Hyde L.A., Hodgson R.A., Lu S.X., McCool M.F., Kazdoba T.M., Vecchio R.A., Guthrie D.H., Pond A.J., and Grzelak M.E. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) 182 (2005) 132-143
54. Venturini G., Stocchi F., Margotta V., Ruggieri S., Bravi D., Bellantuono P., and Palladini G. A pharmacological study of dopaminergic receptors in planaria. Neuropharmacology 28 (1989) 1377-1382
55. Zaveri N.T., Green C.J., Polgar W.E., Huynh N., and Toll L. Regulation of transcription of the human prepronociceptin gene by Sp1. Gene 290 (2002) 45-52
56. Zaveri N.T. Peptide and non-peptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 73 (2003) 663-678
57. Zhao R.J., Woo R.S., Jeong M.S., Shin B.S., Kim D.G., and Kim K.W. Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. Neuroreport 14 (2003) 2383-2385